Executive interview – Cantargia

Executive interview – Cantargia

Associated equity: Cantargia

Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.

Cantargia — 8 videos in collection

Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in a Phase IIa clinical trial, CANFOUR, in solid tumours focusing on NSCLC and pancreatic cancer. Cantargia is also preparing to initiate a trial in the US.

In this video, the company’s chief executive officer Göran Forsberg provides an overview of R&D progress, including a summary of the recently reported interim clinical trial results and expected newsflow.


You may also be interested in these:

Healthcare

Cantargia - executive interview

Healthcare

Cantargia – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free